Anzeige
Mehr »
Donnerstag, 18.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0F57T | ISIN: JP3475350009 | Ticker-Symbol: D4S
Tradegate
17.09.25 | 21:44
20,300 Euro
+0,15 % +0,030
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
DAIICHI SANKYO CO LTD Chart 1 Jahr
5-Tage-Chart
DAIICHI SANKYO CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
20,13020,46017.09.
20,21020,32017.09.

Aktuelle News zur DAIICHI SANKYO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiMRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer6
MoDaiichi Sankyo, Merck Say Raludotatug Deruxtecan Granted Breakthrough Therapy Designation277KENILWORTH (NJ) (dpa-AFX) - Daiichi Sankyo Company Limited (DSKYF) and Merck & Co Inc. (MRK) said on Monday that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy...
► Artikel lesen
11.09.Daiichi Sankyo: ENHERTU Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors294Submission based on three phase 2 trials where Daiichi Sankyo and AstraZeneca's ENHERTU showed clinically meaningful responses across a broad range of tumors If approved, ENHERTU would...
► Artikel lesen
DAIICHI SANKYO Aktie jetzt für 0€ handeln
09.09.Daiichi Jitsugyo: Rekordgewinn im ersten Quartal 2026 bei uneinheitlicher Segmententwicklung6
09.09.Daiichi Sankyo sets up new unit in Shanghai4
08.09.Japanese Drugmaker Daiichi Sankyo Breaks Ground on USD154 Million ADC Facility in Shanghai6
08.09.Daiichi Sankyo And Merck: Ifinatamab Deruxtecan Shows Promising Results In Phase 2 ES-SCLC Trial480KENILWORTH (NJ) (dpa-AFX) - Daiichi Sankyo (DSKYF, 4568.T) and Merck & Co Inc. (MRK) announced that Results from the IDeate-Lung01 phase 2 trial showed that ifinatamab deruxtecan (I-DXd) demonstrated...
► Artikel lesen
30.08.Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to Address Persistent Gaps in the Management of Elevated LDL-C1.064Daiichi Sankyo Europe is pleased to announce the development of a fixed-triple oral combination lipid-lowering tablet of bempedoic acid, ezetimibe, and different doses of a statin, with the potential...
► Artikel lesen
30.08.Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C1.131Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings...
► Artikel lesen
29.08.China to Keep Driving Pharma Industry Transformation, Daiichi Sankyo's China Head Says7
28.08.MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate9
25.08.Daiichi Sankyo and AstraZeneca's Datroway receives approval in China12
21.08.Daiichi Sankyo-Aktie kaum gefragt: Kurs bricht um 5,42 Prozent ein (21,82 €)458Im Wertpapierhandel fällt zur Stunde das Wertpapier von Daiichi Sankyo negativ auf. Das Papier verliert deutlich an Wert. Ein Minus von 5,42 Prozent zeigt die Kurstafel für das Wertpapier von Daiichi...
► Artikel lesen
18.08.Daiichi Sankyo Announces Breakthrough Therapy Designation For Ifinatamab Deruxtecan407KENILWORTH (NJ) (dpa-AFX) - Daiichi Sankyo announced that Ifinatamab deruxtecan has been granted Breakthrough Therapy Designation by the FDA for the treatment of adult patients with extensive-stage...
► Artikel lesen
11.08.Viatris wins FDA nod for generic iron sucrose injection targeting Daiichi's Venofer20
31.07.Daiichi Sankyo reports Q1 results12
31.07.Daiichi Sankyo Q1 Profit Edges Up, Revenues Rise; Confirms FY Outlook526TOKYO (dpa-AFX) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) reported Thursday first-quarter profit attributable to shareholders of 85.50 billion Japanese yen, up 0.1 percent...
► Artikel lesen
18.07.Daiichi Sankyo and AstraZeneca's Enhertu gains breakthrough therapy status29
17.07.AstraZeneca, Daiichi Sankyo get U.S. breakthrough therapy status for Enhertu20
24.06.AstraZeneca, Daiichi's Datroway scores its 2nd FDA approval-this time in lung cancer subset33
Weiter >>
90 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1